News NetraMark Holdings Inc. OTC Markets

Stocks

AINMF

CA64119M1059

Software

Delayed OTC Markets 09:44:03 20/08/2026 pm IST			5-day change	1st Jan Change
0.4326 ^USD	-14.42%		-10.95%	-45.60%

14/08	NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
09/07	NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data	MT

All News

Mentions Relevance

04:31pm	NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High	AQ
14/08	NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
13/07	NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness	AQ
09/07	NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data	MT
09/07	NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	CI
09/07	NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	AQ
29/06	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
29/06	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI
29/06	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	AQ
09/06	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
25/05	Upcoming Meeting Dates - May 25, 2026	NE
20/05	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
15/05	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
15/05	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
08/05	NetraMark Announces Change To Board Of Directors	AQ
08/05	NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026	CI
05/05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE
04/05	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI	AQ
04/05	NetraMark Holdings Inc. Announces Executive Changes	CI
30/04	NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026	AQ
22/04	NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	AQ
22/04	NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	CI
20/04	Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development	AQ
20/04	NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics	CI
09/04	Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes	CI